Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21511255 | 0.91 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL19974443 | 0.89 | KMT2A (0.45) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL19987360 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL21082630 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL13184474 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL21782410 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL13065704 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL5682469 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL13649108 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 | |
| SCHEMBL14853781 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | LCB PHARMA INC. (CA) | 2022-09-27 | — | — | US | disclosed |
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | LCB PHARMA INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | ALDH1A1 3452/4885MAPT 4534/4885POLB 37/4885 |
| US-11434255-B2 | Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2′ position and methods of use as a cardioprotective agent | TNNT2, NT5C2, PNP | ALDH1A1 3260/4885MAPT 4773/4885POLB 298/4885 |
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | PNP, RNGTT, MTAP | ALDH1A1 3857/4885MAPT 4642/4885POLB 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.